News · 26 weeks64-11%
2026-03-012026-08-23
Mix3790d
- Insider13(35%)
- SEC Filings10(27%)
- Other8(22%)
- Earnings3(8%)
- Offering3(8%)
Latest news
25 items- INSIDERChief Science Officer Laing Lance G. was granted 20,000 shares, increasing direct ownership by 2% to 1,271,000 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERChief Executive Officer Sullivan Brian F. was granted 80,000 shares, increasing direct ownership by 6% to 1,450,199 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERChief Financial Officer Hahne Vicky was granted 16,000 shares, increasing direct ownership by 73% to 37,808 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form 10-Q filed by Celcuity Inc.10-Q - Celcuity Inc. (0001603454) (Filer)
- SECCelcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate UpdateREVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026NCCN® Clinical Practice Guidelines recommended REVTORPYK in combination with fulvestrant, with or without palbociclib, as a preferred Category 1 option for second-line therapy in HR+/HER2- advanced breast cancerThe Phase 3 PIK3CA mutant cohort of the VIKTORIA-1 trial achieved its primary endpoint by doubling the likelihood of survival without disease progression or death compared to alpelisib plus fulvestrant; a supplemental New Drug Application ("sNDA") is planned for submission
- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the second quarter 2026 after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-18
- PRNewly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast CancerMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) in combination with fulvestrant, with or without palbociclib, is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1 second-line and/or subsequent-line therapy following progression on or after treatment with at least one line of endocrine therapy. REVTORPYK was granted approval by the U.S. Food and Drug Administration ("FDA") on July 14, 2026, for t
- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
- INSIDERFormer 10% owner Baker Bros. Advisors Lp sold $317,750,000 worth of shares (3,100,000 units at $102.50) (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECAmendment: Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K/A - Celcuity Inc. (0001603454) (Filer)
- FDAFDA Approval for REVTORPYK issued to CELCUITY INC..Submission status for CELCUITY INC..'s drug REVTORPYK (ORIG-1) with active ingredient GEDATOLISIB has changed to 'Approval' on 07/14/2026. Application Category: NDA, Application Number: 219908, Application Classification: Type 1 - New Molecular Entity
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast CancerREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and fulvestrant and REVTORPYK combined with fulvestrant reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrant among patients with PIK3CA wild-type advanced or metastatic breast cancerCelcuity to host webcast and conference call today Tuesday, July 14, 2026, at 5:30 p.m. EDT MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies f
- INSIDERSEC Form 4 filed by Director Murphy Polly A.4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERSEC Form 4 filed by Director Buller Richard E4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Murphy Polly A. was granted 1,530 shares, increasing direct ownership by 31% to 6,530 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Dalvey David was granted 1,530 shares (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Romp Charles R was granted 1,530 shares, increasing direct ownership by 712% to 1,745 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Furcht Leo was granted 1,530 shares, increasing direct ownership by 14% to 12,530 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Nigon Richard was granted 1,530 shares, increasing direct ownership by 2% to 80,565 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Buller Richard E was granted 1,530 shares (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
CELC FAQ
7 questionsWhat does Celcuity Inc. do?
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis...Where does CELC stock trade?
Celcuity Inc. (CELC) is listed on NASDAQ.What sector and industry is CELC in?
Celcuity Inc. operates in the Health Care sector, Medical Specialities industry.When did Celcuity Inc. go public?
Celcuity Inc. (CELC) completed its IPO in 2017.What are analysts saying about CELC?
Celcuity Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-05-04. Recent price targets range from $2900.00 to $3000.00.What companies are similar to CELC?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CELC side-by-side with any of them on Quantisnow.How can I track CELC on Quantisnow?
Quantisnow aggregates Celcuity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELC to receive live email and push alerts on every new disclosure.